Cancer Clinical Trial
Official title:
An Open-label, Multicenter, Phase II Study of PDR001 in Patients With Non-small Cell Lung Cancer Harboring KRAS/NRAS Mutation or Without Actionable Genetic Abnormalities, Detected Using NGS Platform
This study is a phase II, single-arm, open label study. All participating patients must sign on the written informed consent form, and a separate form of consent will be used for the use of tissue for the biomarker research.
This clinical study is targeted for the patients who harbor KRAS/NRAS mutation or no
actionable genetic abnormalities detected using NGS platform and all patients will be treated
with PDR001. The treatment period begins on Day 1 of Cycle 1 and 1 cycle consists of 21 days.
Patients will be continued to receive study drug until the end of study unless the patients
in disease progression, unacceptable toxicity, withdrawn consent, or by the investigator's
judgment.
The progression of the disease in most patients is defined radiographically and determined
according to RECIST criteria ver. 1.1. If there are patients those who need to be provided
investigational drug beyond predefined end of treatment, additional extended providing of
PDR001 needs the mutual agreement of the investigators and Novartis followed by amendment of
study protocol and contract.
At the investigator's discretion, patients who have the initial RECIST PD may continue
PDR001. At any time, if assessed by the investigator that the patient is no longer benefiting
from PDR001, or the patient experiences a second PD by RECIST, then the patient shall come
off study medication.
;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT01285037 -
A Study of LY2801653 in Advanced Cancer
|
Phase 1 | |
| Completed |
NCT00680992 -
Study of Denosumab in Subjects With Giant Cell Tumor of Bone
|
Phase 2 | |
| Completed |
NCT00340522 -
Childhood Cancer and Plexiform Neurofibroma Tissue Microarray for Molecular Target Screening and Clinical Drug Development
|
||
| Recruiting |
NCT03109041 -
Initial Feasibility Study to Treat Resectable Pancreatic Cancer With a Planar LDR Source
|
Phase 1 | |
| Active, not recruiting |
NCT03167372 -
Pilot Comparison of N-of-1 Trials of Light Therapy
|
N/A | |
| Terminated |
NCT01441115 -
ECI301 and Radiation for Advanced or Metastatic Cancer
|
Phase 1 | |
| Completed |
NCT01077414 -
Phenomenological Study of Psycho-Socio-Spiritual Healing in the Context of Chronic or Life-Threatening Illness
|
||
| Completed |
NCT01340846 -
A Pharmacokinetics Study of the Effects of GSK2118436 on Warfarin, the Effects of Ketoconazole and Gemfibrozil on GSK2118436, and the Effects of Repeat Doses of GSK2118436 in Subjects With BRAF Mutant Solid Tumors
|
Phase 1 | |
| Recruiting |
NCT02565004 -
Clinical and Laboratory Analysis of Familial Cancer
|
||
| Active, not recruiting |
NCT02502396 -
Rivaroxaban Utilization for Treatment and Prevention of Thromboembolism in Cancer Patients: Experience at a Comprehensive Cancer Center
|
N/A | |
| Recruiting |
NCT03684005 -
MyPatientPal: An App to Help Patients Manage Their Cancer Care
|
N/A | |
| Not yet recruiting |
NCT03662061 -
Assessment of a Multidisciplinary Team Meeting (RCP) in Geriatric Oncology
|
||
| Recruiting |
NCT03247309 -
TCR-engineered T Cells in Solid Tumors With Emphasis on NSCLC and HNSCC (ACTengine)
|
Phase 1 | |
| Completed |
NCT03272880 -
Utilizing the Arts to Improve Health, Resilience, and Well-Being Among Cancer Patients and Their Caregivers
|
N/A | |
| Active, not recruiting |
NCT00587886 -
Estrogen, Diet, Genetics and Endometrial Cancer
|
||
| Active, not recruiting |
NCT03548077 -
POWERPLAY: Promoting Men's Health at Work
|
N/A | |
| Completed |
NCT03503838 -
A Pilot Study of Online Yoga for MPN Patients
|
N/A | |
| Completed |
NCT00984035 -
Investigation of Cisplatin-Related Kidney Toxicity
|
||
| Completed |
NCT01447186 -
Adaptation of the American Cancer Society (ACS) Early Detection of Prostate Cancer Patient Decision Aid for Spanish Speaking Men
|
N/A | |
| Not yet recruiting |
NCT03257969 -
Impact of the DROP Program on the DRP (Drug Related Problems) Related to Oral Anticancer Drugs in Ambulatory Patients With Risk Factors
|
N/A |
